CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy

[1]  F. Cendes,et al.  The consequences of refractory epilepsy and its treatment , 2014, Epilepsy & Behavior.

[2]  E. Chan,et al.  Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: The clinical implication , 2014, Journal of clinical pharmacology.

[3]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[4]  Mohammad Reza Najafi,et al.  A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012 , 2013, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[5]  H. Derendorf,et al.  Population pharmacokinetics of steady‐state carbamazepine in Egyptian epilepsy patients , 2012, Journal of clinical pharmacy and therapeutics.

[6]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for CYP1A2 , 2012, Pharmacogenetics and genomics.

[7]  R. Altman,et al.  PharmGKB summary: carbamazepine pathway , 2011, Pharmacogenetics and genomics.

[8]  X. Chu,et al.  Functional Evaluation of Genetic and Environmental Regulators of P450 mRNA Levels , 2011, PloS one.

[9]  S. Janković,et al.  Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis. , 2011, International journal of clinical pharmacology and therapeutics.

[10]  L. Bertilsson,et al.  4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. , 2011, British journal of clinical pharmacology.

[11]  E. Thiele,et al.  New drugs for pediatric epilepsy. , 2010, Seminars in pediatric neurology.

[12]  Bo Wang,et al.  Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 , 2010, Drug metabolism reviews.

[13]  S. Janković,et al.  Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism , 2010, European Journal of Clinical Pharmacology.

[14]  Wei Duan,et al.  Insights into the structure, function, and regulation of human cytochrome P450 1A2. , 2009, Current drug metabolism.

[15]  W. Löscher,et al.  The clinical impact of pharmacogenetics on the treatment of epilepsy , 2009, Epilepsia.

[16]  S. Janković,et al.  Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. , 2008, Methods and findings in experimental and clinical pharmacology.

[17]  Wei Yang Lu,et al.  Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine , 2008, Drug Metabolism and Disposition.

[18]  M. Karlsson,et al.  Pharmacodynamics of Carbamazepine‐mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin , 2008, Clinical pharmacology and therapeutics.

[19]  M. Benedetti,et al.  Drug metabolism in the paediatric population and in the elderly. , 2007, Drug discovery today.

[20]  M. Ingelman-Sundberg,et al.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans , 2007, European Journal of Clinical Pharmacology.

[21]  M. Eichelbaum,et al.  Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine , 2006, Clinical pharmacology and therapeutics.

[22]  O. Beck,et al.  Plasma levels of antiepileptic drugs in children on the ketogenic diet. , 2006, Pediatric neurology.

[23]  J. Leeder,et al.  PATHWAYS OF CARBAMAZEPINE BIOACTIVATION IN VITRO: II. THE ROLE OF HUMAN CYTOCHROME P450 ENZYMES IN THE FORMATION OF 2-HYDROXYIMINOSTILBENE , 2005, Drug Metabolism and Disposition.

[24]  Jai Shah.  Criteria influencing the clinical uptake of pharmacogenomic strategies , 2004, BMJ : British Medical Journal.

[25]  J. A. Carrillo,et al.  CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. , 2003, British journal of clinical pharmacology.

[26]  F. Granath,et al.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. , 2002, British journal of clinical pharmacology.

[27]  J. Leeder,et al.  Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[28]  David L. Veenstra,et al.  Assessing the cost-effectiveness of pharmacogenomics , 2000, AAPS PharmSci.

[29]  M. Relling,et al.  Human cytochrome P450 maximal activities in pediatric versus adult liver. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  Sean C. Sweetman,et al.  Martindale: The Complete Drug Reference , 1999 .

[31]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[32]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[33]  U. Fuhr,et al.  Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. , 1999, Pharmacogenetics.

[34]  R. Bergstrom,et al.  A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism , 1998, European Journal of Clinical Pharmacology.

[35]  T. J. Preston,et al.  Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. , 1998, British journal of clinical pharmacology.

[36]  A. Falcão,et al.  Carbamazepine population pharmacokinetics in children: mixed-effect models. , 1997, Therapeutic drug monitoring.

[37]  E. Bresnick,et al.  Identification of positive and negative regulatory elements of the human cytochrome P4501A2 (CYP1A2) gene. , 1997, Archives of biochemistry and biophysics.

[38]  E. Perucca.  Pharmacological problems in the management of epilepsy in children , 1995, Seizure.

[39]  R. Tukey,et al.  The human CYP1A2 gene and induction by 3-methylcholanthrene. A region of DNA that supports AH-receptor binding and promoter-specific induction. , 1994, The Journal of biological chemistry.

[40]  D. Nebert,et al.  Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. , 1989, Molecular endocrinology.

[41]  R. Summers,et al.  Carbamazepine Clearance in Paediatric Epilepsy Patients , 1989, Clinical pharmacokinetics.

[42]  R. Loewenson,et al.  Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children , 1989, Epilepsy Research.

[43]  T. Tomson,et al.  Clinical Pharmacokinetics and Pharmacological Effects of Carbamazepine and Carbamazepine-10,11-Epoxide , 1986 .

[44]  L. Bertilsson,et al.  Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique , 1980, Clinical pharmacology and therapeutics.

[45]  B. Höjer,et al.  Kinetics of carbamazepine and its 10,11‐epoxide metabolite in children , 1976, Clinical pharmacology and therapeutics.

[46]  Sean C. Sweetman.  Comprar Martindale the complete reference 36th Ed, 2 vols + CD-ROM | Sean Sweetman | 9780853698425 | Pharmaceutical Press , 2009 .

[47]  J. Barrett,et al.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. , 2003, British journal of clinical pharmacology.

[48]  D. Reith,et al.  Population Pharmacokinetic Modeling of Steady State Carbamazepine Clearance in Children, Adolescents, and Adults , 2001, Journal of pharmacokinetics and pharmacodynamics.